Skip to main content
. 2021 Jan 18;35(5):1057–1066. doi: 10.1007/s10557-020-07134-2

Fig. 7.

Fig. 7

Subgroup analysis according to the proportion of patients with CKD or DM or patients using RAAS inhibitors in the included studies of change in serum potassium (sK+) between the ZS-9 group and placebo group. SZC, Sodium zirconium cyclosilicate; CKD, chronic kidney disease; DM, diabetic mellitus; RAASi, renin-angiotensin aldosterone system inhibitor